New Measurement Approach Aims to Improve Mixed-Ion Cancer Therapy Precision
Researchers at TU Wien and MedAustron developed a method to measure mixed beams containing carbon and helium ions during cancer treatment. Carbon ions damage tumors while helium ions help track patient anatomy, but the beam's composition must be known accurately. The work, published in Physical Review Accelerators and Beams, could help reduce safety margins and spare healthy tissue.
In ion beam therapy, nuclei are accelerated and aimed at tumors to destroy cancer cells. A proposed mixed beam combines carbon ions, which treat the tumor, with helium ions, which can help verify patient anatomy during irradiation. The carbon-to-helium ratio must be controlled precisely for this monitoring to work.
TU Wien and MedAustron report a measurement approach for such beams, published in Physical Review Accelerators and Beams. Because fully stripped carbon and helium have nearly matching charge-to-mass ratios, they can travel together in an accelerator. In tissue, helium penetrates about three times farther, and its residual energy may reveal how far carbon ions reached.
If validated clinically, this measurement method could help ion therapy centers use mixed carbon-helium beams more reliably. Cancer patients, especially those with tumors near sensitive organs, may benefit from tighter treatment margins and less healthy-tissue exposure. Clinicians and medical physicists could gain better real-time range verification, though adoption may depend on further testing, regulatory review, and integration into existing facilities. It may also influence how future particle therapy systems are designed and commissioned.